What is the official website of Dr. Reddy's Laboratories ?

The official website of Dr. Reddy's Laboratories is http://www.drreddys.com.

What is Dr. Reddy's Laboratories's cybersecurity risk score?

Dr. Reddy's Laboratories has an AI-generated cybersecurity risk score of 783 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Dr. Reddy's Laboratories experienced?

According to Rankiteo, Dr. Reddy's Laboratories currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Dr. Reddy's Laboratories been affected by any supply chain cyber incidents ?

According to Rankiteo, Dr. Reddy's Laboratories has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Dr. Reddy's Laboratories have SOC 2 Type 1 certification ?

According to Rankiteo, Dr. Reddy's Laboratories is not certified under SOC 2 Type 1.

Does Dr. Reddy's Laboratories have SOC 2 Type 2 certification ?

According to Rankiteo, Dr. Reddy's Laboratories does not hold a SOC 2 Type 2 certification.

Does Dr. Reddy's Laboratories comply with GDPR ?

According to Rankiteo, Dr. Reddy's Laboratories is not listed as GDPR compliant.

Does Dr. Reddy's Laboratories have PCI DSS certification ?

According to Rankiteo, Dr. Reddy's Laboratories does not currently maintain PCI DSS compliance.

Does Dr. Reddy's Laboratories comply with HIPAA ?

According to Rankiteo, Dr. Reddy's Laboratories is not compliant with HIPAA regulations.

Does Dr. Reddy's Laboratories have ISO 27001 certification ?

According to Rankiteo,Dr. Reddy's Laboratories is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Dr. Reddy's Laboratories operate in ?

Dr. Reddy's Laboratories operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Dr. Reddy's Laboratories have ?

Dr. Reddy's Laboratories employs approximately 31,653 people worldwide.

Does Dr. Reddy's Laboratories own any subsidiaries ?

Dr. Reddy's Laboratories presently has no subsidiaries across any sectors.

How many LinkedIn followers does Dr. Reddy's Laboratories have ?

Dr. Reddy's Laboratories's official LinkedIn profile has approximately 1,771,584 followers.

What is the NAICS classification code for Dr. Reddy's Laboratories ?

Dr. Reddy's Laboratories is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Dr. Reddy's Laboratories have a Crunchbase profile ?

No, Dr. Reddy's Laboratories does not have a profile on Crunchbase.

Does Dr. Reddy's Laboratories have a LinkedIn profile ?

Yes, Dr. Reddy's Laboratories maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/dr--reddys-laboratories.

How many cybersecurity incidents has Dr. Reddy's Laboratories experienced ?

As of July 18, 2026, Rankiteo reports that Dr. Reddy's Laboratories has not experienced any cybersecurity incidents.

How many peer or competitor companies does Dr. Reddy's Laboratories have ?

Dr. Reddy's Laboratories has an estimated 5,710 peer or competitor companies worldwide.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

DRL

Boost Score +25 with badge (5 left)

783

/1000

Fair

808

/1000

Good

Dr. Reddy's Laboratories Vendor Cyber Rating & Cyber Score

drreddys.com

Add Your Compliance Badge

Established in 1984, we are a global pharmaceutical company headquartered in Hyderabad, India. Driven by our purpose of ‘Good Health Can’t Wait’, we work to provide access to affordable and innovative medicines. We offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major markets include USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in future growth drivers such as access to novel molecules, digital therapeutics and consumer healthcare. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004.

DRL A.I CyberSecurity Scoring

Scoring History

DRL

Dr. Reddy's Laboratories CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

DRL Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for DRL

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Dr. Reddy's Laboratories in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Dr. Reddy's Laboratories in 2026.

Incident Types DRL vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Dr. Reddy's Laboratories in 2026.

Incident History - DRL (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Dr. Reddy's Laboratories Subsidiaries

Parent Company

DRL

Pharmaceutical Manufacturing

Website: http://www.drreddys.com

Company Size: 10,000+ employees

No subsidiary data available for this company.

Loading…

Dr. Reddy's Laboratories Similar Companies

Novo Nordisk

cb novonordisk.com

We’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic disease and create long-term health. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and work to treat, prevent, and even cure diseases that affect millions of lives. Founded in Denmark in 1923, today we employ more than 68,800 people in 80 offices around the world – all united by our bold purpose to drive change to defeat serious chronic diseases. Want to learn more? Visit www.novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to block and remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html

Johnson & Johnson Innovative Medicine

cb jnj.com

At Johnson & Johnson Innovative Medicine, we innovate with purpose, to lead where medicine is going. The experiences of patients around the world inform and inspire our science-based innovations, which continue to change and save lives. Applying rigorous science with compassion, we confidently address the most complex diseases of our time and develop the potential medicines of tomorrow. We are continuously working to develop treatments, aspiring to find cures, pioneering the path from lab to life, and championing patients every step of the way. https://bit.ly/3reuMvK

Viatris

viatris.com

Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale. In 2022 alone, we supplied high-quality medicines to approximately 1 billion patients around the world. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world’s most enduring health challenges, access takes on deep meaning at Viatris. We have the ability to touch all of life’s moments, from birth to end of life, acute conditions to chronic diseases. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India Social Media Guidelines: https://newsroom.viatris.com/social-media-community-guidelines Investors: https://investor.viatris.com Corporate Social Responsibility: https://www.viatris.com/sustainability Connect with Viatris Instagram: https://www.instagram.com/viatrisinc X: https://www.x.com/viatrisinc Viatris and our recruiting firms will not ask for sensitive personal information, such as your social security number, date of birth or bank account details via text, email or social media. Additionally, Viatris representatives do not request payment or personal bank information nor send payment to purchase hardware on your own. Viatris.com is the primary source of all company job postings and authorized third-party career websites.

Zoetis

zoetis.com

The world’s leading animal health company. We’ve been innovating ways to predict, prevent, detect, and treat animal illness for over 70 years, and we continue to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers. Our leading portfolio and pipeline makes a difference in over 100 countries. Community Guidelines: This page is intended to share how Zoetis is advancing care for animals. We aspire to create a supportive community, but there are guidelines to which posts and comments on this page must adhere. If your post references a side effect related to any Zoetis product, we may contact you for more information. To monitor the safety of Zoetis products, we advise you to call our Veterinary Medical Information and Product Support Team at 1-888-963-8471; Support Team is available Mon-Fri 9am to 6:30pm ET. We reserve the right to remove any post/comment that violates LinkedIn Guidelines. As a last resort, we reserve the right to block users that demonstrate a repeated pattern of violating LinkedIn’s spirit of constructive, professional discourse. We respectfully request that you refrain from posting comments including: Unsolicited and/or unverified medical advice Vulgarity and/or profanity Discriminatory and/or derogatory comments, hate speech Politics and religion Personal attacks and/or threats Promotion of illegal activity Copyright/trademark infringements Topics that may be considered spam/advertising Our regular business hours are Mon-Fri 9am to 5pm ET. Zoetis does not endorse and is not responsible for information and opinions shared by community members. The information shared is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. Testimonials represent individual experience only and the experiences and opinions of community members may be unique to the speaker. Terms of Use: https://www.zoetis.com/terms-of-use

SUN PHARMA

sunpharma.com

Sun Pharma is the world's fourth-largest speciality generic pharmaceutical company and No. 1 in India. We provide high-quality, affordable medicines trusted by customers and patients in over 100 countries. Sun Pharma's global presence is supported by more than 40 manufacturing facilities spread across 5 continents, R&D centres across the globe, and a multicultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities comprising around 3,000 scientists and R&D investments of over 6-8% of annual revenues. At Sun, our people are our greatest asset. Ours has never been a story of individual brilliance but of cultivating a culture of realising collective potential. In our journey, everyone is enabled to take charge in an environment that offers limitless growth opportunities. We are with you every step of the way, so you can shine for years to come. With the launch of our Employee Value Proposition (EVP), we define our promise to ‘Create Your Own Sunshine'—driven by the three pillars of Better Every Day, Take Charge, and Thrive Together. These pillars drive progress at Sun so that people can achieve what they would have thought impossible. Learn more about our EVP here: https://sunpharma.com/careers/

Bristol Myers Squibb

cb bms.com

At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome. Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients. Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do. Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html

Teva Pharmaceuticals

tevapharm.com

Teva Pharmaceuticals is a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how we make it happen, visit www.tevapharm.com. Our community guidelines may be found here: https://www.tevapharm.com/news-and-media/teva-social-media-guidelines/ Please note that adverse effects for any of our products should be reported at: https://www.tevapharm.com/teva-medical-information/report-a-side-effect-form/ Product-specific questions should be directed to Teva or Teva Group subsidiaries in your country. Contact details and Teva's Pharmacovigilance Privacy Policy may be found here: http://www.tevapharm.com/contact_us/

MSD

msd.com

At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.msd.com and connect with us on Facebook, Instagram, Twitter, and YouTube.

Grifols

cb linktr.ee

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world. A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions in more than 110 countries. Patient needs and our ever-growing knowledge of many chronic, rare and prevalent diseases, sometimes life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases. With a workforce of over 23,000 employees in more than 30 countries and regions, we are committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry. Our work has a positive social and economic impact in the countries where we operate, creating jobs and generating wealth. People are at the heart of what we do, and we strive to create an inclusive, diverse, fair and equal society. Maintaining and promoting a workforce that reflects this reality leads to enhanced professional relationships and helps us to give our best to patients, donors and customers. In 2024, Grifols was named one of TIME’s ‘World’s Best Companies’ for the second year in a row, reaffirming our commitment to excellence. We were also recognized by Forbes as one of the "Best Employers for Women 2023," reflecting our dedication to fostering an inclusive and supportive workplace for all. To maintain a positive community and overall respectful communication, please keep our community guidelines in mind.

Loading…

NEWS

Dr. Reddy's Laboratories CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

March 31, 2026 11:05 AM

AI, cybersecurity and data skills top India’s critical future capabilities: Report

New Delhi, March 31 (IANS) AI, Cybersecurity, digital and data skills emerged as India's most critical capabilities for the next three to...

Read Article

February 25, 2026 08:00 AM

Top stocks in news: IRFC, Hindalco, Dr Reddys, Waaree, RVNL, Hexaware, Lupin, Schaeffler

Stocks including Tata stocks, IRFC, Hindalco, Dr Reddy's, Aditya Infotech, Waaree, RVNL, Hexaware, Lupin, Schaeffler, Solar stocks and more...

Read Article

January 20, 2026 08:00 AM

Satin Creditcare Network Acquires Majority Stake in Cybersecurity Startup QTrino Labs

Satin Creditcare Network Limited's subsidiary Satin Technologies Limited has acquired up to 76.40% equity stake in QTrino Labs Private...

Read Article

December 28, 2025 08:00 AM

High Growth Indian Stocks Linked to GLP-1 Drugs, Data Centres and Cybersecurity

Over the coming years, structural shifts are set to reshape key sectors of the Indian economy, creating potential investment opportunities.

Read Article

December 03, 2025 08:00 AM

Telangana to unveil quantum strategy on Thursday, outline long-term roadmap

Telangana will unveil its Quantum Strategy on Thursday at IIIT Hyderabad, setting a long-term roadmap for research,...

Read Article

December 02, 2025 08:00 AM

Dr. Reddy's Laboratories Sees Rs. 113.93 Crore Block Trade on NSE

A significant block trade of 888017 shares of Dr Reddy's Laboratories was executed on the National Stock Exchange (NSE) at Rs. 1283.00 per...

Read Article

November 11, 2025 08:00 AM

Dr. Reddy's Laboratories Thwarts Cyber Fraud Attempt, Confirms No Financial Loss

Dr Reddy's Laboratories successfully prevented a cyber fraud attempt involving vendor email impersonation. The hackers tried to redirect a...

Read Article

November 10, 2025 08:00 AM

Bengaluru cyber fraud: Hackers target Dr Reddy’s Lab in scam attempt — How pharma company risked losing o

Cybersecurity News: Dr Reddy's Laboratories lost Rs 2.16 crore to fraudsters who infiltrated an email thread and rerouted a payment to a...

Read Article

November 10, 2025 08:00 AM

India cyber fraud: Dr Reddy’s loses ₹2.16 crore in email impersonation scam

Dr Reddy's Laboratories in India has lost ₹2.16 crore after cyber criminals allegedly hacked email exchanges with Group Pharmaceuticals and...

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-57980

SUMMARY

Authentication bypass using an alternate path or channel in Microsoft Edge (Chromium-based) allows an unauthorized attacker to perform tampering over a network.

Published

Date2026-07-17

Updated

Date2026-07-17

RISK INFORMATION (Score: 5.4)

cvss3

Base Score: 5.4

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:L/I:L/A:N

Impact Score

2.5

Exploitability

2.8

REFERENCES

https://msrc.microsoft.com/update-guide/vulnerability/CVE-2026-57980

CVE-2026-56741

SUMMARY

JLine is a Java library for handling console input. Prior to 3.30.14, 4.0.16, and 4.2.1, the JLine3 Telnet server remote-telnet module does not apply an upper bound to terminal dimensions received via the Telnet NAWS option, and TelnetIO.handleNAWS() in TelnetIO.java:856-879 reads client-supplied width and height as 16-bit unsigned integers and passes values such as 65535x65535 to setTerminalGeometry(), allowing an unauthenticated remote attacker to repeatedly alternate values and trigger continuous expensive rendering work that causes CPU exhaustion and denial of service. This issue is fixed in versions 3.30.14, 4.0.16, and 4.2.1.

Published

Date2026-07-17

Updated

Date2026-07-17

RISK INFORMATION (Score: 7.5)

cvss3

Base Score: 7.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

3.9

REFERENCES

CVE-2026-56740

SUMMARY

JLine is a Java library for handling console input. Prior to 3.30.14, 4.0.16, and 4.2.1, the JLine3 Telnet server remote-telnet module does not limit the number of environment variables a client may inject via the Telnet NEW-ENVIRON option, and TelnetIO.readNEVariables() in TelnetIO.java:1127-1180 stores each variable pair in a HashMap held by ConnectionData, allowing an unauthenticated attacker to flood unique variable pairs before the terminating IAC SE byte and exhaust JVM heap memory with an OutOfMemoryError. This issue is fixed in versions 3.30.14, 4.0.16, and 4.2.1.

Published

Date2026-07-17

Updated

Date2026-07-17

RISK INFORMATION (Score: 7.5)

cvss3

Base Score: 7.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

3.9

REFERENCES

CVE-2026-56171

SUMMARY

Exposure of private personal information to an unauthorized actor in Windows RDP allows an unauthorized attacker to disclose information over a network.

Published

Date2026-07-17

Updated

Date2026-07-17

RISK INFORMATION (Score: 7.1)

cvss3

Base Score: 7.1

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:H/I:L/A:N

Impact Score

4.2

Exploitability

2.8

REFERENCES

https://msrc.microsoft.com/update-guide/vulnerability/CVE-2026-56171

CVE-2026-54335

SUMMARY

Feathersjs is a framework for creating web APIs and real-time applications with TypeScript or JavaScript. In 5.0.44 and earlier, the _.merge(target, source) utility exported by @feathersjs/commons recursively merges source into target by iterating Object.keys(source). When source was produced by JSON.parse and contains a __proto__, constructor, or prototype key, that key is returned as an own-enumerable property; the recursive merge then resolves target['__proto__'] to Object.prototype and writes attacker-supplied properties onto it, polluting the prototype for all plain objects in the process for the lifetime of the Node process. This issue is fixed in version 5.0.45.

Published

Date2026-07-17

Updated

Date2026-07-17

RISK INFORMATION (Score: 3.7)

cvss3

Base Score: 3.7

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:N/I:L/A:N

Impact Score

1.4

Exploitability

2.2

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…